CERE

Cerevel Therapeutics Holdings Inc.

Price

return (12m)

p/e

-30.70

p/bv

14.50

DIVIDEND YIELD

0.00%

CERE price

Cerevel Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment CERE

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals CERE

Valuation

P/E

-30.70

Sector -3.50

Industry -3.50

P/BV

14.50

Sector 2.01

Industry 2.01

P/Revenue (PSR)

Sector 2.01

Industry 2.01

EV/EBITDA

-66.79

Sector -223.67

Industry -223.67

EV/EBIT

-65.99

Sector -47.92

Industry -47.92

P/EBITDA

-23.20

Sector -21.50

Industry -21.50

P/EBIT

-23.00

Sector -28.21

Industry -28.21

P/Total Assets

7.26

Sector 1.19

Industry 1.19

P/Net Current Assets

27.58

Sector -10.26

Industry -10.26

P/Working Capital

10.55

Sector -167.98

Industry -167.98

EPS

-1.46

Sector -1.79

Industry -1.79

BVPS

3.10

Sector 2.06

Industry 2.06

Efficiency

Gross Margin

0.00%

Sector 41.30%

Industry 41.30%

EBITDA Margin

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

Sector -4,185,659.35%

Industry -4,185,659.35%

Operating Margin

0.00%

Sector -35.21%

Industry -35.21%

Net Profit Margins

0.00%

Sector -35.91%

Industry -35.91%

Asset Turnover

0.00

Sector 0.02

Industry 0.02

Profitability

ROE

-47.22%

Sector -56.67%

Industry -56.67%

ROA

-23.64%

Sector -59.91%

Industry -59.91%

ROIC

-211.52%

Sector -2,335.95%

Industry -2,335.95%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

10.22

Sector 2.89

Industry 2.89

Net Debt / EBITDA

-2.65

Sector -14,066,680.10

Industry -14,066,680.10

Net Debt / EBIT

-2.62

Sector -8.06

Industry -8.06

Net Debt / Equity

0.60

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

0.60

Sector -0.85

Industry -0.85

Equity/Assets

0.50

Sector 0.46

Industry 0.46

Liabilities/Assets

0.50

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

3.41%

Sector -

Industry -

Fundamentals CERE

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
CERE Cerevel Therapeutics Holdings Inc.	$0.00	-	0.00%	-30.70	14.50	-47.22%	0.00%
JNJ Johnson & Johnson	$270.61	56.72%	1.96%	30.82	7.63	24.76%	21.48%
PFE Pfizer Inc.	$28.50	26.43%	6.26%	35.85	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$263.75	22.26%	2.59%	73.99	-78.76	-106.44%	9.81%
NVO Novo Nordisk A/S	$38.47	-31.25%	4.29%	10.56	5.61	53.11%	35.32%
MRK Merck & Co. Inc.	$149.22	93.94%	2.31%	113.21	8.55	7.55%	4.76%
AZN AstraZeneca PLC	$164.92	11.31%	1.94%	19.88	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$60.81	43.25%	4.04%	13.67	5.68	41.55%	18.85%
ZTS Zoetis Inc.	$70.80	-49.40%	2.88%	11.47	9.64	84.02%	27.77%
AMGN Amgen Inc.	$405.08	45.13%	2.60%	23.66	17.70	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$798.06	38.86%	0.47%	18.63	2.54	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$114.66	47.81%	0.00%	31.57	90.97	288.13%	24.86%
MCK McKesson Corporation	$881.77	19.56%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$523.68	37.91%	0.00%	29.15	6.34	21.76%	35.00%
CAH Cardinal Health Inc.	$224.25	46.88%	0.91%	30.53	-19.32	-63.29%	0.68%
ARGX argenx SE	$952.35	29.68%	0.00%	2.24	2.63	117.11%	44.68%
HRMY Harmony Biosciences Holdings Inc.	$41.31	28.80%	0.00%	13.50	2.45	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

CERE Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Cerevel Therapeutics

Cerevel Therapeutics Holdings Inc.

Average Investor10 user rating

4.0 (1 people)

United States

8 years

Founded: 2018

2020

Time since IPO - 6 years

104

Employees

Cerevel Therapeutics Holdings Inc. (United States) is listed on the Nasdaq and has a market capitalization of $8.18 billion, with shareholders equity totaling $564.46 million.

The company employs approximately 104 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Cerevel Therapeutics Holdings Inc. reported $- in revenue, generating net income of $-266.51 million.

Key financial metrics include a P/E ratio of -30.70, a price-to-book (P/B) ratio of 14.50, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker CERE.

Market cap

$8.18 billion

Net worth

$564.46 million

$564,460,000.00

Assets

$1.13 billion

$1,127,340,000.00

Total Shares Outstanding

182.00 million

182,000,000

Average Daily Trading Volume

$2.15 million

$2,147,005.36

Sector

Health Care

Industry

Biotechnology

CERE

CERE revenue and profits

Financial Results CERE

DRAG THE FRAME TO SEE MORE DATA

CERE cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$881.77 16,53% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$224.25 46,92% (12M)

P/E

30.53

0.91%

ROE

-63.29%

P/BV

-19.32

JNJ - Johnson & Johnson

$270.61 56,62% (12M)

P/E

30.82

1.96%

ROE

24.76%

P/BV

7.63

ABBV - AbbVie

$263.75 23,72% (12M)

P/E

73.99

2.59%

ROE

-106.44%

P/BV

-78.76

MRK - Merck & Co.

$149.22 94,65% (12M)

P/E

113.21

2.31%

ROE

7.55%

P/BV

8.55

AZN - AstraZeneca

$164.92 14,08% (12M)

P/E

19.88

1.94%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$28.50 26,64% (12M)

P/E

35.85

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$881.77 16,53% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$224.25 46,92% (12 M)

P/L

30.53

0.91%

ROE

-63.29%

P/VP

-19.32

JNJ - Johnson & Johnson

$270.61 56,62% (12 M)

P/L

30.82

1.96%

ROE

24.76%

P/VP

7.63

ABBV - AbbVie

$263.75 23,72% (12 M)

P/L

73.99

2.59%

ROE

-106.44%

P/VP

-78.76

MRK - Merck & Co.

$149.22 94,65% (12 M)

P/L

113.21

2.31%

ROE

7.55%

P/VP

8.55

AZN - AstraZeneca

$164.92 14,08% (12 M)

P/L

19.88

1.94%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$28.50 26,64% (12 M)

P/L

35.85

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Cerevel Therapeutics (CERE) today?

The current price of Cerevel Therapeutics (CERE) is $0.00. The stock began the year trading around $0.00 and is currently priced at $0.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Cerevel Therapeutics (CERE) pay dividends?

Cerevel Therapeutics (CERE) did not pay dividends over the past year.

Is Cerevel Therapeutics (CERE) a good investment?

Cerevel Therapeutics (CERE) is currently trading at $0.00 with a P/E ratio of -30.70. This represents a -2,712% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Cerevel Therapeutics (CERE) stock?

You can buy Cerevel Therapeutics (CERE) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol CERE and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Cerevel Therapeutics (CERE) yield today?

Over the past month, Cerevel Therapeutics (CERE) has returned 0.00% — 0.00% over the past year, and 0.00% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Cerevel Therapeutics (CERE) today at the current price of $0.00 your total investment would be $0.00.

Based on historical performance, the investment would have grown to approximately:

$0.00 after 1 year
$0.00 after 5 years
$0.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

CERE

Cerevel Therapeutics Holdings Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment CERE

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING CERE WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Cerevel Therapeutics

Cerevel Therapeutics Holdings Inc.

United States

8 years

2020

104

PROFIT X PRICE CERE

Financial Results CERE

CERE cash flow

Asset, Revenue and Profit Growth - CERE

CERE balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions